

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051458 A1

(51) International Patent Classification⁷: **A61P 27/02**,
A61K 31/555

J., Jr. [US/US]; 3701 Big Bear Lake Drive, Arlington, TX 76016 (US). **HELLBERG, Mark, R.** [US/US]; 2545 Glen Ridge Drive, Highland Village, TX 75077 (US).

(21) International Application Number: PCT/US02/39037

(22) International Filing Date: 6 December 2002 (06.12.2002)

(74) Agents: **YEAGER, Sally, S.** et al.; R & D Counsel, Mail Code Q-148, 6201 South Freeway, Fort Worth, TX 76134 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AU, BR, CA, CN, JP, KR, MX, PL, US, ZA.

(30) Priority Data:
60/340,389 14 December 2001 (14.12.2001) US

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(71) Applicants (*for all designated States except US*): **ALCON, INC.** [CH/CH]; P.O. Box 62, Bosch 69, CH-6331 Hünenberg (CH). **KLIMKO, Peter, G.** [US/US]; 2115 Pembroke Drive, Ft. Worth, TX 76110 (US).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLLIER, Robert,**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/051458 A1

(54) Title: SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES

(57) Abstract: The use of SOD mimics particularly pentaazacycle Mn(II) complex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.


SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES

5 The present invention relates to mimics of the enzyme superoxide dismutase for the treatment of the exudative and non-exudative forms of age-related macular degeneration, diabetic retinopathy, and retinal edema.

Background of the Invention

10 Age-related macular degeneration (AMD) is the most common cause of vision impairment in the elderly population in western countries. The exudative or "wet" form of AMD is characterized by excessive neovascularization of the choroid, leading to retinal detachment and vision
15 loss. The non-exudative or "dry" form is characterized by the accumulation of cellular debris called drusen in Bruch's membrane below the retinal pigmented epithelium (RPE). Exudative AMD, which occurs in a minority of patients with AMD, but is the more aggressive form of the disease, can be treated with limited success by laser photocoagulation therapy or
20 photodynamic therapy. The latter procedure involves dosing of the affected area with a compound which, when irradiated with the appropriate wavelength of light, generates a reactive intermediate that destroys surrounding blood vessels. Currently there is no accepted therapy for the treatment of non-exudative AMD.

25 The visual cycle begins in photoreceptor cells with the absorption of a photon by an opsin-bound Schiff base of 11-*cis* retinal, which isomerizes to the corresponding all-*trans* retinal derivative. Release of the all-*trans* retinal from opsin is followed by condensation with phosphatidylethanolamine to
30 form the new Schiff base NRPE (for N-Retinyl Phosphatidyl Ethanolamine). The NRPE so formed is transported across the photoreceptor cell outer membrane, where it is hydrolyzed to all-*trans* retinal. Enzymatic reduction to all-*trans* retinol is followed by transport into the RPE cell, where the compound is enzymatically isomerized to 11-*cis* retinol and oxidized to 11-*cis*
35 retinal. This compound is transported back to the photoreceptor cell, where it forms an opsin-bound Schiff base to complete the cycle.




Besides helping to complete the visual cycle by recycling retinal, an important function of RPE cells is to support the continuous remodeling of retinal photoreceptors by phagocytosing their discarded outer segments and digesting them in RPE cell lysosomes. With age occurs the accumulation of a non-digestible pigment called lipofuscin in the lysosomes (the appearance of drusen is thought to correspond to lipofuscin accumulation). Lipofuscin absorbs light in the blue part of the spectrum and fluoresces in the yellow part of the spectrum. This fluorescence transfers energy to nearby oxygen, which becomes transformed into reactive oxygen species (ROS), such as superoxide ion. These ROS oxidize lysosomal membrane phospholipids, destroying membrane integrity. With membrane integrity breached the toxic contents of the lysosome leach into the cytosol, leading to RPE cell death. Without their supporting RPE cells retinal photoreceptors cannot participate in the visual transduction system, thus leading to blindness (for a review, see Winkler, et. al., Mol. Vision, Vol. 5:32, 1999, online journal; <http://www.molvis.org/molvis/v5/p32>; CA 132:235390).

20

Nakanishi and co-workers have elucidated the structure of and chemically synthesized the major fluorescent constituent of lipofuscin, called A2E (Nakanishi et. al., Proc. Natl. Acad. Sci. USA, Vol. 95:14609-14613, 1998, and references therein). This compound is thought to result biosynthetically from isomerization of electrophilic NRPE to the nucleophilic

25

enamine **1**, followed by condensation with another molecule of all-*trans* retinal to form azatriene **2**, electrocyclic ring closure to dihydropyridine **3**, autoxidation to the N-(2-hydroxyethyl)pyridinium species A2PE, and enzymatic hydrolysis of the phosphate ester by the enzyme phospholipase D to afford A2E. The chemical structure of A2E—a molecule with two large hydrophobic “tails” and a charged polar “head”—suggests a detergent-like propensity to breach cell membranes. Along with its photooxidative capabilities, this may form an important component of the compound’s toxic effects on RPE cells (for a review, see: Nakanishi et. al., Bioorganic and Medicinal Chemistry Letters, Vol. 11:1533-1540, 2001).




The key role of defective transport of all-*trans* retinal out of the photoreceptor cell in the AMD disease process has been highlighted by the discovery that a genetic mutation that when homozygously present leads to a rare rapid macular degeneration called Stargardt's Disease may be associated, when heterozygously expressed, with non-exudative AMD (Dean et. al., Science, Vol. 277:1805-1807, 1997). The gene is called the ABCR gene (for ATP Binding Cassette Transporter Retina), whose protein product (also called rim protein) utilizes the energy released upon ATP hydrolysis to transport molecules across cell membranes. It is thought that the transporter's substrate is the Schiff base NRPE mentioned above. Absent sufficient functional transporter protein, the substrate NRPE accumulates in the photoreceptor cell instead of being shuttled out for reduction to retinol. Condensation with a molecule of all *trans*-retinal liberated from opsin and further reaction as mentioned above produces A2E. The A2E is ingested by RPE cells with the rest of the photoreceptor cell outer segment, where it accumulates in the lysosome. Supporting this hypothesis is the disclosure by Travis et. al. that A2E accumulation in RPE cells occurs much more rapidly in mice that are homozygously mutant in the ABCR gene, as compared to normal controls (Travis et. al., Proc. Natl. Acad. Sci. USA, Vol. 97:7154-7159, 2000).

Several studies have concluded that exposure of lipofuscin to light and oxygen under conditions mimicking those present in the retina leads to cell membrane peroxidation and cell death. Wihlmark et. al. disclosed that blue light irradiation of RPE cells with lipofuscin-loaded lysosomes increased cell membrane peroxidation and decreased cell viability, as compared to controls irradiated in the absence of lipofuscin (Wihlmark et. al., Free Radical Biol. Med. Vol. 22:1229-1234, 1997). Boulton and Shamsi have disclosed that dosing of cultured RPE cells with lipofuscin and exposing them to light decreased cell viability by over 40% after 24 hours and decreased lysosomal enzymatic and antioxidant activity, including that of superoxide dismutase (SOD) (Boulton and Shamsi, Invest. Ophthalmol. Vis. Sci., Vol. 42:3041-3046, 2001).

From this and other evidence, it is clear that certain defects in the body's natural defense mechanisms for dealing with toxic by-products of oxidative metabolism may play an important role in the development of AMD. One important component of this defense system is the SOD enzyme family.

These enzymes contain a low valent metal (either Mn^{II} or a Cu^I/Zn^I binuclear linkage) which catalyze the disproportionation of the highly reactive superoxide radical anion to the less toxic entities O₂ and H₂O₂. If not quenched the superoxide anion can (*via* its protonated form) abstract hydrogens from the allylic sites of fatty acids, leading to membrane damage. Additionally superoxide anion can react with NO to produce peroxynitrite, a potent oxidizing agent that is believed to be an important player in the untoward biological effects of excessive NO production.




The potential importance of SOD in enhancing RPE cell viability is suggested by the disclosure of Boulton et. al, who. have reported that the damaging effects caused by irradiation of lipid membranes, proteins, and enzymes in the presence of lipofuscin can be significantly reduced by the addition of SOD (Boulton et. al., J Biol. Chem., Vol. 274:23828-23832, 1999). Even with respect to exudative AMD, a recent study in Japanese subjects disclosed a significant correlation between this form of the disease and a mutation in the SOD gene, corresponding to a valine/alanine substitution in the targeting sequence of the enzyme (Isashiki et. al., Am. J. Ophthalmol., Vol. 130:769-773, 2000). Thus, enhancing SOD function may be a viable target for preventing the development of both the exudative and non-exudative forms of AMD.


Oxidative stress also contributes to diabetes induced vascular and neural dysfunction. All forms of diabetes result in the development of diabetes specific microvascular pathology of the retina, renal glomerulus and peripheral nerve (M. Brownlee, "Biochemistry and Molecular Cell Biology of Diabetic Complications", Nature, Vol. 414:813-820, 2001). A prime source of the oxidative insult associated with diabetes is elevated levels of superoxide. Release of superoxide was detected in human blood vessels isolated from, patients with diabetes (Guzik, et al., "Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus" Circulation, Vol. 105:1656-62, 2002). Sources of superoxide include the vascular tissues and polymorphonuclear leukocytes (Shurtz-Swirski et al., "Involvement of Peripheral Polymorphonuclear Leukocytes in Oxidative Stress and Inflammation in Type 2 Diabetic Patients," Diabetes Care, Vol. 24:104-110,

2001). Superoxide Dismutase mimics have been shown to delay the onset of diabetes (AEOL10113 – Piganelli, et al., "A Metalloporphyrin-Based Superoxide Dismutase Mimic Inhibits Adoptive Transfer of Autoimmune Diabetes by a Diabetogenic T-cell Clone," Diabetes, Vol. 51:347-55, 2002.) in
5 a cloned cell and prevented vascular and neural dysfunction in diabetic rats (M40403 – Coppey, et al., "Effect of M40403 Treatment of Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Velocity and Vascular Function of Epineural Arterioles of the Siatic Nerve," British Journal of Pharmacology, Vol. 134:21-9, 2001). In patients with diabetic retinopathy
10 serum level of lipid peroxides are higher than in healthy normals or patients with diabetes that do not have diabetic retinopathy. While levels of SOD remain the same in diabetics and normals, levels of ascorbic acid, a key antioxidant, are lower in all diabetics (Gurler, et al., "The Role of Oxidative Stress in Diabetic Retinopathy" Eye, Vol. 14:73035, 2000) The results of
15 these studies suggest that endogenous antioxidant mechanisms are overwhelmed in patients with diabetic retinopathy.

The use of intravenously dosed Mn SOD itself to treat or prevent oxidative stress-related tissue injury in humans, such as tissue damage due
20 to cerebral or myocardial ischemia-reperfusion injury, has been unsuccessful due to bioavailability and immunogenic issues. These problems are thought to be due to the fact that Mn SOD is a high molecular weight species. A low molecular weight compound that catalyzes superoxide disproportionation with efficiency comparable to endogenous Mn SOD would be a good candidate for
25 minimizing the aforementioned side effects. Salvemini et. al. have disclosed a class of Mn(II)-pentaaza macrocycle complexes as low molecular weight SOD mimics. For example, in a rat model of intestinal ischemia-reperfusion, 90% of animals dosed with 1 mg/kg of compound 4 survived after 4 h, compared to 0% survival for untreated animals [Salvemini, et. al., Science,
30 Vol. 286:304, 1999; WO 98/58636; Salvemini, et al., Drugs Future, Vol. 25(10):1027, 2000], These compounds have also been disclosed for enhancing the stability of implanted biopolymeric prosthetic devices (including ocular implants; Ornberg et. al., WO 00/72893 A2) and for the treatment of pain (Salvemini et. al., U.S. Patent Nos. 6,180,620 B1 and 6,214,817B1).



The use of certain Mn-salen complexes as SOD and catalase mimics with therapeutic activity has also been disclosed. For example, compound 5 has been shown to be neuroprotective in a rat stroke model (Baker et. al., J. Pharmacol. Exp. Ther., Vol. 284:215-221, 1998; Doctrow et. al., J. Med. Chem., Vol. 45:4549-4558, 2002), while compound 6 was found to increase the lifespan of mice that were deficient in endogenous expression of the enzyme superoxide dismutase 2 (Melov et. al., J. Neurosci., Vol. 21:8348-8353, 2001).



Other investigators have reported the use of antioxidant compounds to treat ocular diseases. Crapo et. al., have disclosed the use of porphyrin-containing SOD mimics for treating glaucoma and macular degeneration (Crapo et. al., U.S. Patent Nos. 5,994,339 and 6,127,356). Campbell et. al. have disclosed the use of certain bipyridyl Mn(II or III)phenolate complexes for treating free-radical associated diseases (Campbell et. al., U.S. Patent No. 6,177,419 B1). Levin has disclosed the use of carvedilol and its derivatives and metabolites as scavengers of ROS to reduce retinal ganglion cell death (WO 00/07584 A2). Brownlee has disclosed the use of a manganese tetrakis(benzoic acid) porphyrin for reducing ROS accumulation under high glucose conditions for treating diabetic retinopathy (Brownlee, WO 00/19993 A2). The stable free radical 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl, a metal-free SOD mimic, has been reported to inhibit light-induced retinal damage in albino rats (Wang et. al., Res. Commun. Mol. Pathol. Pharmacol., Vol. 89:291-305, 1995). However, in none of these reports were the compounds of the present invention disclosed or suggested for the treatment of AMD.

Summary of the Invention

This application is directed to the use of mimics of the enzyme, superoxide dismutase to treat persons suffering from the exudative and non-exudative forms of AMD, diabetic retinopathy, which includes preproliferative diabetic retinopathy (collectively DR) and retinal edema.

Detailed Description of the Invention


Posterior segment neovascularization is the vision-threatening pathology responsible for the two most common causes of acquired blindness in developed countries: exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). Currently the only approved treatments for the posterior segment NV that occurs during exudative AMD are laser photocoagulation or photodynamic therapy with Visudyne®; both therapies involve occlusion of affected vasculature which results in localized laser-induced damage to the retina. Surgical interventions with vitrectomy and membrane removal are the only options currently available for patients with proliferative diabetic retinopathy. No strictly pharmacologic treatment has been approved for use against posterior segment NV, although several different compounds are being evaluated clinically, including, for example, anecortave acetate (Alcon, Inc.), EYE 001 (Eyetechnology), and rhuFabV2 (Genentech) for AMD and LY333531 (Lilly) and Fluocinolone (Bausch & Lomb) for diabetic macular edema.

In addition to changes in the retinal microvasculature induced by hyperglycemia in diabetic patients leading to macular edema, proliferation of neovascular membranes is also associated with vascular leakage and edema of the retina. Where edema involves the macula, visual acuity worsens. In diabetic retinopathy, macular edema is the major cause of vision loss. Like angiogenic disorders, laser photocoagulation is used to stabilize or resolve the edematous condition. While reducing further development of edema, laser photocoagulation is a cytotoxic procedure, that, unfortunately will alter the visual field of the affected eye.

An effective pharmacologic therapy for ocular NV and edema would likely provide substantial efficacy to the patient, in many diseases thereby avoiding invasive surgical or damaging laser procedures. Effective treatment

of the NV and edema would improve the patient's quality of life and productivity within society. Also, societal costs associated with providing assistance and health care to the blind could be dramatically reduced.

It has now been discovered that certain SOD mimics are useful for the treatment of AMD, DR, and retinal edema. These compounds are of formula I:



I

wherein:

R^{1-20} are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl, each of which is optionally substituted with an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxy carbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

or two of the R groups on the same (e.g., R^1 and R^2 , or R^3 and R^4 , or R^5 and R^6 , etc.) or adjacent (e.g., R^1 and R^3 , or R^3 and R^5 , or R^6 and R^7 , etc.) sites, together with the carbon atoms to which they are attached, form an optionally unsaturated or aromatic C_{3-20} carbocycle, the carbocycle being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxy carbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

or two of the R groups on the same (e.g., R^1 and R^2 , or R^3 and R^4 , or R^5 and R^6 , etc.) or adjacent (e.g., R^1 and R^3 , or R^3 and R^5 , or R^6 and R^7 , etc.) sites, together with the carbon atoms to which they are attached, form an optionally unsaturated or aromatic C_{2-20} nitrogen-containing heterocycle, the heterocycle being optionally substituted optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl,

halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

it being understood that in all cases the nitrogens binding the Mn center in the drawing for I will lack hydrogens when the nitrogen is already trisubstituted (e.g., when the relevant nitrogen is part of a pyridine ring);

X, Y, and Z are pharmaceutically acceptable anions; and

n is 0-3.

Compounds I of the present invention are known, and their syntheses are disclosed in US Patent No. 6,214,817 B1, which is herein incorporated by reference.

As used herein, the terms "pharmaceutically acceptable anion" means any anion that would be suitable for therapeutic administration to a patient by any conventional means without significant deleterious health consequences. Examples of preferred pharmaceutically acceptable anions include chloride, bromide, acetate, benzoate, maleate, fumarate, and succinate.

The term "free hydroxy group" means an OH. The term "functionally modified hydroxy group" means an OH which has been functionalized to form: an ether, in which an alkyl group is substituted for the hydrogen; an ester, in which an acyl group is substituted for the hydrogen; a carbamate, in which an aminocarbonyl group is substituted for the hydrogen; or a carbonate, in which an alkoxycarbonyl group is substituted for the hydrogen. Examples of preferred groups include OH, OC(O)CH₃, OCH₃, OPh, OCH₂Ph, and OC(O)Ph.

The term "free amino group" means an N₂. The term "functionally modified amino group" means an NH₂ which has been functionalized to form: an alkoxyamino or hydroxyamino group, in which an alkoxy or hydroxy group is substituted for one of the hydrogens; an alkylamino group, in which an alkyl group is substituted for one or both of the hydrogens; an amide, in which an acyl group is substituted for one of the hydrogens; a carbamate, in which an alkoxycarbonyl group is substituted for one of the hydrogens; or a urea, in which an aminocarbonyl group is substituted for one of the hydrogens.

Combinations of these substitution patterns, for example an NH_2 in which one of the hydrogens is replaced by an alkyl group and the other hydrogen is replaced by an alkoxycarbonyl group, also fall under the definition of a functionally modified amino group and are included within the scope of the present invention. Examples of preferred groups include NH_2 , NHCH_3 , $\text{N}(\text{CH}_3)_2$, NPh , $\text{NHC}(\text{O})\text{Ph}$, $\text{NHC}(\text{O})\text{CH}_3$, $\text{NHC}(\text{O})\text{OCH}_3$, and $\text{NHC}(\text{O})\text{OPh}$.

The term "free thiol group" means an SH . The term "functionally modified thiol group" means an SH which has been functionalized to form: a thioether, where an alkyl, aryl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, or heteroaryl group is substituted for the hydrogen; or a thioester, in which an acyl group is substituted for the hydrogen. Examples of preferred moieties include SH , SPh , $\text{SC}(\text{O})\text{CH}_3$, SCH_3 , SC_2H_5 , $\text{SC}(\text{CH}_3)_3$, S-cyclohexyl , $\text{SCH}_2\text{CO}_2\text{CH}_3$, $\text{SCH}_2\text{CO}_2\text{C}_2\text{H}_5$, $\text{SCH}_2\text{C}(\text{O})\text{C}_2\text{H}_5$, and $\text{SCH}_2\text{C}(\text{O})\text{CH}_3$.

The term "acyl" represents a group that is linked by a carbon atom that has a double bond to an oxygen atom and a single bond to another carbon atom.

The term "alkyl" includes straight or branched chain aliphatic hydrocarbon groups that are saturated and have 1 to 15 carbon atoms. The alkyl groups may be substituted with other groups, such as halogen, hydroxyl or alkoxy. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and *t*-butyl.

The term "cycloalkyl" includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more rings, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "alkenyl" includes straight or branched chain hydrocarbon groups having 1 to 15 carbon atoms with at least one carbon-carbon double bond. The chain hydrogens may be substituted with other groups, such as halogen. Preferred straight or branched alkenyl groups include, allyl, 1-butenyl, 1-methyl-2-propenyl and 4-pentenyl.

The term "cycloalkenyl" includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more non-aromatic rings containing a carbon-carbon double bond, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkenyl groups include cyclopentenyl and cyclohexenyl.

The term "alkoxy" represents an alkyl group attached through an oxygen linkage.

The term "carbonyl group" represents a carbon atom double bonded to an oxygen atom, wherein the carbon atom has two free valencies.

The term "alkoxycarbonyl" represents an alkoxy group bonded from its oxygen atom to the carbon of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.

The term "aminocarbonyl" represents an amino group bonded from its nitrogen atom to the carbon atom of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.

The term "lower alkyl" represents alkyl groups containing one to six carbons (C_1 - C_6).

The term "halogen" represents fluoro, chloro, bromo, or iodo.

The term "aryl" refers to carbon-based rings which are aromatic. The rings may be isolated, such as phenyl, or fused, such as naphthyl. The ring hydrogens may be substituted with other groups, such as lower alkyl, or halogen.

The term "heteroaryl" refers to aromatic hydrocarbon rings which contain at least one heteroatom such as O, S, or N in the ring. Heteroaryl rings may be isolated, with 5 to 6 ring atoms, or fused, with 8 to 10 atoms. The heteroaryl ring(s) hydrogens or heteroatoms with open valency may be substituted with other groups, such as lower alkyl or halogen. Examples of heteroaryl groups include imidazole, pyridine, indole, quinoline, furan,

thiophene, pyrrole, tetrahydroquinoline, dihydrobenzofuran, and dihydrobenzindole.

5 Preferred compounds of the present invention include those of formula I, wherein:

$R^7R^8C-N-CR^9R^{10}$ forms a 5-8 membered saturated or unsaturated (including aromatic) ring, the ring being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxy carbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;


$R^5, R^6, R^{11}, R^{12}, R^{17}, R^{18}, R^{19}$, and R^{20} are the same or different and are H or alkyl;

15 $R^1R^2C-CR^3R^4$ and $R^{13}R^{14}C-CR^{15}R^{16}$ are the same or different and form a 5-8 membered saturated or unsaturated (including aromatic) ring, the ring being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxy carbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

X and Y are chloride; and

25 n is 0.

The most preferred compounds of the present invention include the following:



The syntheses of these compounds is disclosed in U.S. Patent No. 6,214,817 B1.

5

The SOD mimics may be contained in various types of pharmaceutical compositions, in accordance with formulation techniques known to those skilled in the art. For example, the compounds may be included in tablets, capsules, solutions, suspensions, and other dosage forms adapted for oral administration; solutions and suspensions adapted for parenteral use; and solutions and suspensions adapted for topical ophthalmic, depot, or intra-ocular injection. Solutions, suspensions, and other dosage forms adapted for depot, oral, intra-ocular injection, and topical ophthalmic administration, such as eye drops or tissue irrigating solutions, are particularly preferred for the prevention or treatment of acute or chronic retinal or optic nerve head damage. Compositions can also be delivered topically to the eye according to the teachings in WO 96/05840, which is herein incorporated by reference.

15

The present invention is also directed to the provision of compositions adapted for treatment of retinal and optic nerve head tissues. The ophthalmic compositions of the present invention will include one or more SOD mimics and a pharmaceutically acceptable vehicle. Various types of vehicles may be

20

used. The vehicles will generally be aqueous in nature. Aqueous solutions are generally preferred, based on ease of formulation, as well as a patient's ability to easily administer such compositions by means of instilling one to two drops of the solutions in the affected eyes. However, the SOD mimics of the present invention may also be readily incorporated into other types of compositions, such as suspensions, viscous or semi-viscous gels, or other types of solid or semi-solid compositions. Suspensions may be preferred for SOD mimics that are relatively insoluble in water. The ophthalmic compositions of the present invention may also include various other ingredients, such as buffers, preservatives, co-solvents, and viscosity building agents.

An appropriate buffer system (e.g., sodium phosphate, sodium acetate or sodium borate) may be added to prevent pH drift under storage conditions.

Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% weight/volume ("% w/v").

The route of administration (e.g., topical, ocular injection, parenteral, or oral) and the dosage regimen will be determined by skilled clinicians, based on factors such as the exact nature of the condition being treated, the severity of the condition, and the age and general physical condition of the patient.

In general, the doses used for the above described purposes will vary, but will be in an effective amount to prevent or treat AMD, DR, and retinal edema. As used herein, the term "pharmaceutically effective amount" refers to an amount of one or more SOD mimics which will effectively treat AMD, DR, and/or retinal edema in a human patient. The doses used for any of the above-described purposes will generally be from about 0.01 to about 100 milligrams per kilogram of body weight (mg/kg), administered one to four times per day. When the compositions are dosed topically, they will generally be in a concentration range of from 0.001 to about 5% w/v, with 1-2 drops administered 1-4 times per day.

As used herein, the term "pharmaceutically acceptable carrier" refers to any formulation that is safe, and provides the appropriate delivery for the desired route of administration of an effective amount of at least one compound of the present invention.

5

The following Examples 1 and 2 are formulations useful for intraocular, periocular, or retrobulbar injection or perfusion.

EXAMPLE 1

10

Component	% w/v
Compound of formula I	0.1
Dibasic sodium phosphate	0.2
HPMC	0.5
Polysorbate 80	0.05
Benzalkonium chloride	0.01
<u>Sodium chloride</u>	0.75
Edetate disodium	0.01
NaOH/HCl	q.s. to pH 7.4
Purified water	q.s. to 100%

EXAMPLE 2

Component	% w/v
Compound of formula I	0.1
<u>Cremophor EL</u>	10
Tromethamine	0.12
Boric acid	0.3
Mannitol	4.6
Edetate disodium	0.1
<u>Benzalkonium chloride</u>	0.1
NaOH/HCl	q.s. to pH 7.4
Purified water	q.s. to 100%

EXAMPLE 3

5

The following tablet formulation can be made pursuant to U.S. Patent No. 5,049,586, incorporated herein by reference.

Component	% w/v
Compound of formula I	60
Magnesium oxide	20
Corn starch	15
<u>Polyvinylpyrrolidone</u>	3
Sodium carboxymethylcellulose	1
Magnesium stearate	0.8


10

The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the

invention being indicated by the appended claims rather than by the foregoing description.

We Claim:

1. A method for treating AMD, DR, and/or retinal edema in a patient which comprises administering to the patient in need of such treatment a pharmaceutically effective amount of a compound of formula I:



wherein:

R^{1-20} are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl, each of which is optionally substituted with an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxy carbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

or two of the R groups on the same (e.g., R^1 and R^2 , or R^3 and R^4 , or R^5 and R^6 , etc.) or adjacent (e.g., R^1 and R^3 , or R^3 and R^5 , or R^6 and R^7 , etc.) sites, together with the carbon atoms to which they are attached, form an optionally unsaturated or aromatic C_{3-20} carbocycle, the carbocycle being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxy carbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

or two of the R groups on the same (e.g., R^1 and R^2 , or R^3 and R^4 , or R^5 and R^6 , etc.) or adjacent (e.g., R^1 and R^3 , or R^3 and R^5 , or R^6 and R^7 , etc.) sites, together with the carbon atoms to which they are attached, form an optionally unsaturated or aromatic C_{2-20} nitrogen-containing heterocycle, the heterocycle being optionally substituted optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl,

halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

it being understood that in all cases the nitrogens binding the Mn center in the drawing for I will lack hydrogens when the nitrogen is already trisubstituted (e.g., when the relevant nitrogen is part of a pyridine ring);

X, Y, and Z are pharmaceutically acceptable anions; and

n is 0-3.

2. The method of claim 1, wherein for the compound of formula I: $R^7R^8C-N-CR^9R^{10}$ forms a 5-8 membered saturated or unsaturated (including aromatic) ring, the ring being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;


R^5 , R^6 , R^{11} , R^{12} , R^{17} , R^{18} , R^{19} , and R^{20} are the same or different and are H or alkyl;

$R^1R^2C-CR^3R^4$ and $R^{13}R^{14}C-CR^{15}R^{16}$ are the same or different and form a 5-8 membered saturated or unsaturated (including aromatic) ring, the ring being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group;

X and Y are chloride; and

n is 0.

3. The method of claim 3, wherein the compound is selected from the group consisting of:



INTERNATIONAL SEARCH REPORT

PCT/US 02/39037

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P27/02 A61K31/555

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA, EMBASE, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 214 817 B1 (KUSTURIN CARRIE L ET AL) 10 April 2001 (2001-04-10) abstract examples ---	1-3
Y	KIMURA KATSUAKI ET AL: "Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration." AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 130, no. 6, December 2000 (2000-12), pages 769-773, XP001146383 ISSN: 0002-9394 the whole document --- -/--	1-3



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

31 March 2003

Date of mailing of the international search report

11/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Skjöldebrand, C

INTERNATIONAL SEARCH REPORT

PCT/US 02/39037

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 127 356 A (CRAPO JAMES D ET AL) 3 October 2000 (2000-10-03) cited in the application column 26, line 50-53 ---	1-3
Y	US 5 209 926 A (BABCOCK JOHN C ET AL) 11 May 1993 (1993-05-11) column 2, line 52-65 ---	1-3
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; Accession number: PREV199192011255 , 1991 SZABO M E; DROY-LEFAIX M T; DOLY M; CARRE C; BRAQUET P : "ISCHEMIA AND REPERFUSION-INDUCED HISTOLOGIC CHANGES IN THERAT RETINA DEMONSTRATION OF A FREE RADICAL-MEDIATED MECHANISM" XP002236627 Full-text article published in "Investigative Ophthalmology & Visual Science", Vol. 32, Nr. 5, pages 1471-1478 abstract ---	1-3
Y	WO 99 23097 A (UNIV DUKE) 14 May 1999 (1999-05-14) page 13, line 9-12 -----	1-3

INTERNATIONAL SEARCH REPORT

international application No.
PCT/US 02/39037

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-3 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US 02/39037

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6214817	B1	10-04-2001	US 6180620 B1	30-01-2001
			AU 7702400 A	17-04-2001
			EP 1212323 A2	12-06-2002
			WO 0119823 A2	22-03-2001
			US 6395725 B1	28-05-2002
			US 2002128248 A1	12-09-2002
			AU 733415 B2	17-05-2001
			AU 8068598 A	04-01-1999
			EP 1001752 A1	24-05-2000
			JP 2002506445 T	26-02-2002
			WO 9858636 A1	30-12-1998
			ZA 9805376 A	21-06-1999
			US 6127356	A
AU 725602 B2	12-10-2000			
AU 6387096 A	30-12-1996			
CA 2223407 A1	19-12-1996			
EP 0831891 A1	01-04-1998			
JP 11509180 T	17-08-1999			
WO 9640223 A1	19-12-1996			
AU 702596 B2	25-02-1999			
AU 7976394 A	04-05-1995			
CA 2174236 A1	20-04-1995			
EP 0723398 A1	31-07-1996			
JP 9505805 T	10-06-1997			
WO 9510185 A1	20-04-1995			
US 5747026 A	05-05-1998			
US 5209926	A	11-05-1993		
			US 5538721 A	23-07-1996
			US 5332582 A	26-07-1994
			AT 163853 T	15-03-1998
			AU 8090791 A	07-01-1992
			CA 2085245 A1	13-12-1991
			DE 69129078 D1	16-04-1998
			DE 69129078 T2	12-11-1998
			DK 660717 T3	21-12-1998
			EP 0660717 A1	05-07-1995
			ES 2116292 T3	16-07-1998
			JP 5507916 T	11-11-1993
			NZ 238240 A	26-08-1993
			WO 9119482 A1	26-12-1991
			US 5252319 A	12-10-1993
			US 5256408 A	26-10-1993
			ZA 9103908 A	26-02-1992
			WO 9923097	A
AU 1297999 A	24-05-1999			
CA 2309154 A1	14-05-1999			
EP 1045851 A1	25-10-2000			
JP 2001521939 T	13-11-2001			
WO 9923097 A1	14-05-1999			
US 2002042407 A1	11-04-2002			